

# Mara Dierssen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7589887/publications.pdf>

Version: 2024-02-01

187  
papers

9,883  
citations

31976

53  
h-index

46799

89  
g-index

209  
all docs

209  
docs citations

209  
times ranked

10452  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal in vivo Imaging of the Integrated Postnatal Development of Brain and Skull and Its Co-modulation With Neurodevelopment in a Down Syndrome Mouse Model. <i>Frontiers in Medicine</i> , 2022, 9, 815739.	2.6	4
2	COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. <i>Vaccines</i> , 2022, 10, 530.	4.4	8
3	Müller glia fused with adult stem cells undergo neural differentiation in human retinal models. <i>EBioMedicine</i> , 2022, 77, 103914.	6.1	3
4	Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4210-4215.	3.6	9
5	Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome. <i>Scientific Reports</i> , 2021, 11, 4715.	3.3	15
6	Effects of COVID-19 Home Confinement on Mental Health in Individuals with Increased Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1015-1021.	2.6	8
7	Medical vulnerability of individuals with Down syndrome to severe COVID-19—data from the Trisomy 21 Research Society and the UK ISARIC4C survey. <i>EClinicalMedicine</i> , 2021, 33, 100769.	7.1	73
8	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. <i>NeuroMolecular Medicine</i> , 2021, 23, 561-571.	3.4	30
9	Altered Genetic Expression Disrupts Facial Ontogenetic Trajectory in Down Syndrome and <i>DYRK1A</i> Haploinsufficiency. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
10	Environmental Enrichment Induces Epigenomic and Genome Organization Changes Relevant for Cognition. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 664912.	2.9	12
11	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 621440.	4.8	26
12	Editorial: Brain Insulin Resistance in Neurodevelopmental and Neurodegenerative Disorders: Mind the Gap!. <i>Frontiers in Neuroscience</i> , 2021, 15, 730378.	2.8	4
13	Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3748.	2.4	7
14	Meta-analysis of transcriptomic data reveals clusters of consistently deregulated gene and disease ontologies in Down syndrome. <i>PLoS Computational Biology</i> , 2021, 17, e1009317.	3.2	13
15	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. <i>Molecular Syndromology</i> , 2021, 12, 202-218.	0.8	6
16	Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19. <i>Scientific Reports</i> , 2021, 11, 1930.	3.3	35
17	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. <i>Journal of Clinical Medicine</i> , 2021, 10, 5125.	2.4	24
18	Social Factors Influence Behavior in the Novel Object Recognition Task in a Mouse Model of Down Syndrome. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 772734.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management. <i>Clinical Nutrition</i> , 2020, 39, 1292-1300.	5.0	23
20	A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. <i>Clinical Nutrition</i> , 2020, 39, 378-387.	5.0	16
21	The Value of Mouse Models of Rare Diseases: A Spanish Experience. <i>Frontiers in Genetics</i> , 2020, 11, 583932.	2.3	12
22	Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions. <i>Frontiers in Neuroscience</i> , 2020, 14, 670.	2.8	48
23	Lessons from individuals with Down syndrome during COVID-19. <i>Lancet Neurology</i> , The, 2020, 19, 974-975.	10.2	5
24	Rethinking Intellectual Disability from Neuro- to Astro-Pathology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9039.	4.1	10
25	Re-establishment of the epigenetic state and rescue of kinome deregulation in Ts65Dn mice upon treatment with green tea extract and environmental enrichment. <i>Scientific Reports</i> , 2020, 10, 16023.	3.3	15
26	Behavioral Phenotyping for Down Syndrome in Mice. <i>Current Protocols in Mouse Biology</i> , 2020, 10, e79.	1.2	8
27	ViceCT and whiceCT for simultaneous high-resolution visualization of craniofacial, brain and ventricular anatomy from micro-computed tomography. <i>Scientific Reports</i> , 2020, 10, 18772.	3.3	4
28	Prefrontalâ€“hippocampal functional connectivity encodes recognition memory and is impaired in intellectual disability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11788-11798.	7.1	45
29	Ethanol-Induced Changes in Brain of Transgenic Mice Overexpressing DYRK1A. <i>Molecular Neurobiology</i> , 2020, 57, 3195-3205.	4.0	3
30	Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome. <i>Progress in Brain Research</i> , 2020, 251, 269-302.	1.4	13
31	A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction. <i>Nature Communications</i> , 2020, 11, 782.	12.8	70
32	Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with FontupÂ® Dietary Supplement: Role of Green Tea Catechins. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1404.	4.1	16
33	Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome. <i>Progress in Brain Research</i> , 2020, 251, 245-268.	1.4	16
34	Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome. <i>Neurobiology of Disease</i> , 2019, 125, 92-106.	4.4	26
35	Pergola-web: a web server for the visualization and analysis of longitudinal behavioral data using repurposed genomics tools and standards. <i>Nucleic Acids Research</i> , 2019, 47, W600-W604.	14.5	2
36	DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 272.	2.9	21

#	ARTICLE	IF	CITATIONS
37	Metabolomics predicts the pharmacological profile of new psychoactive substances. <i>Journal of Psychopharmacology</i> , 2019, 33, 347-354.	4.0	21
38	Protocol for Measuring Compulsive-like Feeding Behavior in Mice. <i>Bio-protocol</i> , 2019, 9, e3308.	0.4	1
39	Extinction and reinstatement of an operant responding maintained by food in different models of obesity. <i>Addiction Biology</i> , 2018, 23, 544-555.	2.6	11
40	Time-course and dynamics of obesity-related behavioral changes induced by energy-dense foods in mice. <i>Addiction Biology</i> , 2018, 23, 531-543.	2.6	13
41	Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome. <i>Free Radical Biology and Medicine</i> , 2018, 114, 122-130.	2.9	21
42	Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society. <i>Molecular Syndromology</i> , 2018, 9, 279-286.	0.8	8
43	Pergola: Boosting Visualization and Analysis of Longitudinal Data by Unlocking Genomic Analysis Tools. <i>IScience</i> , 2018, 9, 244-257.	4.1	5
44	Neuroprotective Properties of Wine. , 2018, , 271-284.		0
45	Mutations in L-type amino acid transporter-2 support SLC7A8 as a novel gene involved in age-related hearing loss. <i>ELife</i> , 2018, 7, .	6.0	38
46	Computational Models. , 2018, , 105-131.		2
47	Translating molecular advances in Down syndrome and Fragile X syndrome into therapies. <i>European Neuropsychopharmacology</i> , 2018, 28, 675-690.	0.7	14
48	Overweight Mice Show Coordinated Homeostatic and Hedonic Transcriptional Response across Brain. <i>ENeuro</i> , 2018, 5, ENEURO.0287-18.2018.	1.9	1
49	Anomalous White Matter Structure and the Effect of Age in Down Syndrome Patients. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 61-70.	2.6	32
50	New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease. <i>Scientific Reports</i> , 2017, 7, 41931.	3.3	23
51	Loss of SIRT2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance. <i>Aging Cell</i> , 2017, 16, 1404-1413.	6.7	36
52	Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear. <i>Neuropsychopharmacology</i> , 2017, 42, 462-472.	5.4	13
53	Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders. <i>Neural Plasticity</i> , 2016, 2016, 1-20.	2.2	18
54	VNTR-DAT1 and COMT Val158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 193.	2.0	10

#	ARTICLE	IF	CITATIONS
55	Overexpression of <i>Dyrk1A</i> , a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex. <i>Journal of Neuroscience</i> , 2016, 36, 3648-3659.	3.6	54
56	Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society. <i>Molecular Syndromology</i> , 2016, 7, 251-261.	0.8	16
57	Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 801-810.	10.2	227
58	Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns. <i>Translational Psychiatry</i> , 2016, 6, e718-e718.	4.8	137
59	Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain. <i>Amino Acids</i> , 2016, 48, 103-116.	2.7	8
60	Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome. <i>ENeuro</i> , 2016, 3, ENEURO.0103-16.2016.	1.9	42
61	Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease. <i>Current Drug Targets</i> , 2016, 18, 174-195.	2.1	51
62	Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges. <i>BMC Genomics</i> , 2015, 16, 907.	2.8	30
63	Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma A $\beta$ 42 Concentrations in Down Syndrome Young Adults. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 301.	2.0	23
64	Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 330.	2.0	44
65	A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. <i>Frontiers in Psychology</i> , 2015, 6, 708.	2.1	53
66	RhoE deficiency alters postnatal subventricular zone development and the number of calbindin-expressing neurons in the olfactory bulb of mouse. <i>Brain Structure and Function</i> , 2015, 220, 3113-3130.	2.3	10
67	Opposite Phenotypes of Muscle Strength and Locomotor Function in Mouse Models of Partial Trisomy and Monosomy 21 for the Proximal Hspa13-App Region. <i>PLoS Genetics</i> , 2015, 11, e1005062.	3.5	39
68	From neural to genetic substrates of panic disorder: Insights from human and mouse studies. <i>European Journal of Pharmacology</i> , 2015, 759, 127-141.	3.5	14
69	A cluster of protein kinases and phosphatases modulated in fetal Down syndrome (trisomy 21) brain. <i>Amino Acids</i> , 2015, 47, 1127-1134.	2.7	3
70	Potential Role of Olive Oil Phenolic Compounds in the Prevention of Neurodegenerative Diseases. <i>Molecules</i> , 2015, 20, 4655-4680.	3.8	181
71	New Perspectives for the Rescue of Cognitive Disability in Down Syndrome. <i>Journal of Neuroscience</i> , 2015, 35, 13843-13852.	3.6	28
72	Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. <i>Cortex</i> , 2015, 64, 148-156.	2.4	64

#	ARTICLE	IF	CITATIONS
73	DREAM Controls the On/Off Switch of Specific Activity-Dependent Transcription Pathways. <i>Molecular and Cellular Biology</i> , 2014, 34, 877-887.	2.3	41
74	Cognition and Hippocampal Plasticity in the Mouse Is Altered by Monosomy of a Genomic Region Implicated in Down Syndrome. <i>Genetics</i> , 2014, 197, 899-912.	2.9	18
75	Hippocampal changes produced by overexpression of the human CHRNA5/A3/B4 gene cluster may underlie cognitive deficits rescued by nicotine in transgenic mice. <i>Acta Neuropathologica Communications</i> , 2014, 2, 147.	5.2	6
76	The $\alpha 4\beta 2$ nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies. <i>British Journal of Pharmacology</i> , 2014, 171, 3845-3857.	5.4	34
77	Epigallocatechin gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 278-288.	3.3	234
78	Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage. <i>Neurobiology of Disease</i> , 2014, 69, 65-75.	4.4	104
79	Heterozygous deletion of the Williams-Beuren syndrome critical interval in mice recapitulates most features of the human disorder. <i>Human Molecular Genetics</i> , 2014, 23, 6481-6494.	2.9	69
80	Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: Implications for Down syndrome. <i>Neurobiology of Disease</i> , 2014, 63, 92-106.	4.4	17
81	The role of nicotinic receptors in shaping and functioning of the glutamatergic system: A window into cognitive pathology. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 46, 315-325.	6.1	25
82	Targeting the endocannabinoid system in the treatment of fragile X syndrome. <i>Nature Medicine</i> , 2013, 19, 603-607.	30.7	203
83	Carnitine palmitoyltransferase 1C deficiency causes motor impairment and hypoactivity. <i>Behavioural Brain Research</i> , 2013, 256, 291-297.	2.2	38
84	ErbB4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. <i>Neuron</i> , 2013, 79, 1152-1168.	8.1	254
85	Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. <i>Neurobiology of Disease</i> , 2013, 60, 18-31.	4.4	66
86	A commentary on: Overexpression of Dyrk1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. <i>Experimental Neurology</i> , 2013, 247, 110-112.	4.1	0
87	Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. <i>Neurobiology of Disease</i> , 2013, 52, 117-127.	4.4	67
88	AGC malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. <i>Journal of Neurochemistry</i> , 2013, 124, 347-362.	3.9	15
89	Functional implications of hippocampal adult neurogenesis in intellectual disabilities. <i>Amino Acids</i> , 2013, 45, 113-131.	2.7	13
90	DNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease. <i>Brain</i> , 2013, 136, 3018-3027.	7.6	129

#	ARTICLE	IF	CITATIONS
91	Hippocampal Hyperexcitability Underlies Enhanced Fear Memories in Tg <i>&lt;i&gt;NTRK3&lt;/i&gt;</i> , a Panic Disorder Mouse Model. <i>Journal of Neuroscience</i> , 2013, 33, 15259-15271.	3.6	30
92	Dyrk1A Is Dynamically Expressed on Subsets of Motor Neurons and in the Neuromuscular Junction: Possible Role in Down Syndrome. <i>PLoS ONE</i> , 2013, 8, e54285.	2.5	26
93	NGF Upregulates the Plasminogen Activation Inhibitor-1 in Neurons via the Calcineurin/NFAT Pathway and the Down Syndrome-Related Proteins DYRK1A and RCAN1 Attenuate This Effect. <i>PLoS ONE</i> , 2013, 8, e67470.	2.5	15
94	Neuropathology and Synaptic Alterations in Neurodevelopmental Disorders. , 2013, , 980-994.		0
95	Preface. <i>Progress in Brain Research</i> , 2012, 197, vii.	1.4	0
96	Dyrk1A Influences Neuronal Morphogenesis Through Regulation of Cytoskeletal Dynamics in Mammalian Cortical Neurons. <i>Cerebral Cortex</i> , 2012, 22, 2867-2877.	2.9	84
97	Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3136-45.	7.1	155
98	Down syndrome: the brain in trisomic mode. <i>Nature Reviews Neuroscience</i> , 2012, 13, 844-858.	10.2	230
99	Ceramide Levels Regulated by Carnitine Palmitoyltransferase 1C Control Dendritic Spine Maturation and Cognition. <i>Journal of Biological Chemistry</i> , 2012, 287, 21224-21232.	3.4	71
100	Overexpression of $\alpha 5$ nicotinic receptor subunits modifies impulsive-like behavior. <i>Drug and Alcohol Dependence</i> , 2012, 122, 247-252.	3.2	12
101	Aberrant brain microRNA target and miRISC gene expression in the anx/anx anorexia mouse model. <i>Gene</i> , 2012, 497, 181-190.	2.2	12
102	Therapeutic approaches in the improvement of cognitive performance in Down syndrome. <i>Progress in Brain Research</i> , 2012, 197, 1-14.	1.4	53
103	Reduced Mid1 Expression and Delayed Neuromotor Development in daDREAM Transgenic Mice. <i>Frontiers in Molecular Neuroscience</i> , 2012, 5, 58.	2.9	15
104	Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. <i>Amino Acids</i> , 2012, 43, 897-909.	2.7	36
105	Transgenic over expression of nicotinic receptor alpha 5, alpha 3, and beta 4 subunit genes reduces ethanol intake in mice. <i>Alcohol</i> , 2012, 46, 205-215.	1.7	30
106	Behavioral Characterization of a Mouse Model Overexpressing DSCR1/ RCAN1. <i>PLoS ONE</i> , 2011, 6, e17010.	2.5	42
107	RhoE Deficiency Produces Postnatal Lethality, Profound Motor Deficits and Neurodevelopmental Delay in Mice. <i>PLoS ONE</i> , 2011, 6, e19236.	2.5	39
108	Effects of age on $\alpha 1$ -adrenoceptor subtypes in the heart ventricular muscle of the rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 907-909.	2.4	8



#	ARTICLE	IF	CITATIONS
109	A gel-based proteomic method reveals several protein pathway abnormalities in fetal Down syndrome brain. <i>Journal of Proteomics</i> , 2011, 74, 547-557.	2.4	25
110	G-Protein-Associated Signal Transduction Processes Are Restored after Postweaning Environmental Enrichment in Ts65Dn, a Down Syndrome Mouse Model. <i>Developmental Neuroscience</i> , 2011, 33, 442-450.	2.0	19
111	Overexpression of Reelin Prevents the Manifestation of Behavioral Phenotypes Related to Schizophrenia and Bipolar Disorder. <i>Neuropsychopharmacology</i> , 2011, 36, 2395-2405.	5.4	85
112	In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. <i>Amino Acids</i> , 2010, 39, 1571-1580.	2.7	24
113	Cognitive deficits and associated neurological complications in individuals with Down's syndrome. <i>Lancet Neurology</i> , The, 2010, 9, 623-633.	10.2	372
114	Susceptibility to stress in transgenic mice overexpressing TrkC, a model of panic disorder. <i>Journal of Psychiatric Research</i> , 2010, 44, 157-167.	3.1	18
115	Î²-amyloid controls altered Reelin expression and processing in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2010, 37, 682-691.	4.4	53
116	Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. <i>Neurobiology of Disease</i> , 2010, 40, 348-359.	4.4	49
117	Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2. <i>Genes, Brain and Behavior</i> , 2010, 9, 160-172.	2.2	23
118	Down Syndrome: From Understanding the Neurobiology to Therapy. <i>Journal of Neuroscience</i> , 2010, 30, 14943-14945.	3.6	133
119	Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome. <i>Neuroscience</i> , 2010, 170, 453-467.	2.3	40
120	Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 429-438.	1.4	8
121	Increased opioid dependence in a mouse model of panic disorder. <i>Frontiers in Behavioral Neuroscience</i> , 2009, 3, 60.	2.0	10
122	Aneuploidy: From a Physiological Mechanism of Variance to Down Syndrome. <i>Physiological Reviews</i> , 2009, 89, 887-920.	28.8	106
123	A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. <i>Human Molecular Genetics</i> , 2009, 18, 4756-4769.	2.9	101
124	Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice. <i>Neurobiology of Disease</i> , 2009, 36, 312-319.	4.4	24
125	RESEARCH FOCUS ON COMPULSIVE BEHAVIOUR IN ANIMALS: An animal model of compulsive food-taking behaviour. <i>Addiction Biology</i> , 2009, 14, 373-383.	2.6	63
126	Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: Involvement of phospholipase C $\beta$ 3 activity and glutamate receptor expression. <i>Neuroscience</i> , 2009, 158, 1234-1250.	2.3	98



#	ARTICLE	IF	CITATIONS
127	Protein expression of BACE1, BACE2 and APP in Down syndrome brains. <i>Amino Acids</i> , 2008, 35, 339-343.	2.7	77
128	Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome. <i>American Journal of Human Genetics</i> , 2008, 83, 479-488.	6.2	60
129	Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. <i>Neurobiology of Disease</i> , 2008, 32, 377-384.	4.4	41
130	Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. <i>Human Molecular Genetics</i> , 2008, 17, 1234-1244.	2.9	50
131	Fibrinogen drives dystrophic muscle fibrosis via a TGF $\beta$ <sup>2</sup> /alternative macrophage activation pathway. <i>Genes and Development</i> , 2008, 22, 1747-1752.	5.9	222
132	Hypothalamus transcriptome profile suggests an anorexia-cachexia syndrome in the anx/anx mouse model. <i>Physiological Genomics</i> , 2008, 35, 341-350.	2.3	22
133	Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for the Dual Specificity Tyrosine-Regulated Kinase-1A (Dyrk1A). <i>PLoS ONE</i> , 2008, 3, e2575.	2.5	87
134	Dissociation between CA3-CA1 Synaptic Plasticity and Associative Learning in TgNTRK3 Transgenic Mice. <i>Journal of Neuroscience</i> , 2007, 27, 2253-2260.	3.6	44
135	uPA deficiency exacerbates muscular dystrophy in MDX mice. <i>Journal of Cell Biology</i> , 2007, 179, 165-165.	5.2	1
136	uPA deficiency exacerbates muscular dystrophy in MDX mice. <i>Journal of Cell Biology</i> , 2007, 178, 1039-1051.	5.2	66
137	Fetal Down Syndrome Brains Exhibit Aberrant Levels of Neurotransmitters Critical for Normal Brain Development. <i>Pediatrics</i> , 2007, 120, e1465-e1471.	2.1	101
138	Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, Dyrk1A+/. <i>Genes, Brain and Behavior</i> , 2007, 6, 569-578.	2.2	25
139	Understanding the human brain through mouse models. <i>Genes, Brain and Behavior</i> , 2007, 6, 1-1.	2.2	203
140	Candidate genes for panic disorder: insight from human and mouse genetic studies. <i>Genes, Brain and Behavior</i> , 2007, 6, 2-23.	2.2	25
141	Differential responses to anxiogenic drugs in a mouse model of panic disorder as revealed by Fos immunocytochemistry in specific areas of the fear circuitry. <i>Amino Acids</i> , 2007, 33, 677-688.	2.7	13
142	DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis. <i>Scientific World Journal</i> , The, 2006, 6, 1911-1922.	2.1	81
143	Brain G protein-dependent signaling pathways in Down syndrome and Alzheimer's disease. <i>Amino Acids</i> , 2006, 31, 449-456.	2.7	18
144	Pitfalls And Hopes in Down Syndrome Therapeutic Approaches: In the Search for Evidence-Based Treatments. <i>Behavior Genetics</i> , 2006, 36, 454-468.	2.1	17

#	ARTICLE	IF	CITATIONS
145	Dendritic pathology in mental retardation: from molecular genetics to neurobiology. <i>Genes, Brain and Behavior</i> , 2006, 5, 48-60.	2.2	166
146	Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. <i>Neurobiology of Disease</i> , 2006, 24, 403-418.	4.4	50
147	Alterations in the phenotype of neocortical pyramidal cells in the <i>Dyrk1A</i> <sup>+/-</sup> mouse. <i>Neurobiology of Disease</i> , 2005, 20, 115-122.	4.4	94
148	Constitutive <i>Dyrk1A</i> is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. <i>Neurobiology of Disease</i> , 2005, 20, 392-400.	4.4	152
149	Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. <i>Brain Research</i> , 2004, 1022, 101-109.	2.2	108
150	On dendrites in Down syndrome and DS murine models: a spiny way to learn. <i>Progress in Neurobiology</i> , 2004, 74, 111-126.	5.7	124
151	Motor phenotypic alterations in <i>TgDyrk1a</i> transgenic mice implicate <i>DYRK1A</i> in Down syndrome motor dysfunction. <i>Neurobiology of Disease</i> , 2004, 15, 132-142.	4.4	75
152	Haploinsufficiency of <i>Dyrk1A</i> in Mice Leads to Specific Alterations in the Development and Regulation of Motor Activity.. <i>Behavioral Neuroscience</i> , 2004, 118, 815-821.	1.2	61
153	<i>Dyrk1A</i> expression pattern supports specific roles of this kinase in the adult central nervous system. <i>Brain Research</i> , 2003, 964, 250-263.	2.2	125
154	Special interest section - Down's syndrome: postgenomic approaches to neurobiological problems. <i>Genes, Brain and Behavior</i> , 2003, 2, 152-155.	2.2	5
155	Alterations of Neocortical Pyramidal Cell Phenotype in the <i>Ts65Dn</i> Mouse Model of Down Syndrome: Effects of Environmental Enrichment. <i>Cerebral Cortex</i> , 2003, 13, 758-764.	2.9	136
156	Long-Chain Polyunsaturated Fatty Acids in Rat Maternal Milk, Offspring Brain and Peripheral Tissues in Essential Fatty Acid Deficiency. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 278-84.	2.3	7
157	Postnatal Handling Induces Long-term Modifications in Central $\beta$ -noradrenergic Signalling in Rats. <i>Stress</i> , 2002, 5, 137-147.	1.8	9
158	<i>Dyrk1A</i> Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice. <i>Molecular and Cellular Biology</i> , 2002, 22, 6636-6647.	2.3	306
159	Differential effects of environmental enrichment on behavior and learning of male and female <i>Ts65Dn</i> mice, a model for Down syndrome. <i>Behavioural Brain Research</i> , 2002, 134, 185-200.	2.2	156
160	Neurobehavioral development of two mouse lines commonly used in transgenic studies. <i>Pharmacology Biochemistry and Behavior</i> , 2002, 73, 19-25.	2.9	46
161	Proteomic analysis of the fetal brain. <i>Proteomics</i> , 2002, 2, 1547-1576.	2.2	68
162	Murine models for Down syndrome. <i>Physiology and Behavior</i> , 2001, 73, 859-871.	2.1	62

#	ARTICLE	IF	CITATIONS
163	Reduced phospholipase C $\alpha$ 2 activity and isoform expression in the cerebellum of TS65DN mouse: A model of down syndrome. <i>Journal of Neuroscience Research</i> , 2001, 66, 540-550.	2.9	19
164	Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. <i>Human Molecular Genetics</i> , 2001, 10, 1915-1923.	2.9	357
165	Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. <i>Brain Research</i> , 2000, 858, 191-197.	2.2	115
166	The Mouse Brain Transcriptome by SAGE: Differences in Gene Expression between P30 Brains of the Partial Trisomy 16 Mouse Model of Down Syndrome (Ts65Dn) and Normals. <i>Genome Research</i> , 2000, 10, 2006-2021.	5.5	81
167	The Mouse Brain Transcriptome by SAGE: Differences in Gene Expression between P30 Brains of the Partial Trisomy 16 Mouse Model of Down Syndrome (Ts65Dn) and Normals. <i>Genome Research</i> , 2000, 10, 2006-2021.	5.5	13
168	Chapter 5.9 Modelling Down syndrome in mice. <i>Handbook of Behavioral Neuroscience</i> , 1999, 13, 895-913.	0.0	1
169	A murine model for Down syndrome shows reduced responsiveness to pain. <i>NeuroReport</i> , 1999, 10, 1119-1122.	1.2	56
170	Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome. <i>Neuroscience Letters</i> , 1998, 247, 171-174.	2.1	149
171	Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of down syndrome. <i>Neuroscience Letters</i> , 1998, 253, 175-178.	2.1	137
172	Cholinergic, serotonergic and catecholaminergic neurons are not affected in Ts65Dn mice. <i>NeuroReport</i> , 1997, 8, 3475-3478.	1.2	29
173	Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. <i>Brain Research</i> , 1997, 749, 238-244.	2.2	97
174	Impaired cyclic AMP production in the hippocampus of a Down syndrome murine model. <i>Developmental Brain Research</i> , 1996, 95, 122-124.	1.7	48
175	A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. <i>Neuroscience Letters</i> , 1995, 199, 143-146.	2.1	233
176	Action on noradrenergic transmission of an anticholinesterase: 9-amino-1,2,3,4-tetrahydroacridine. <i>Neuropharmacology</i> , 1995, 34, 367-375.	4.1	3
177	Early Environmental Stimulation Produces Long-Lasting Changes on $\beta$ -Adrenoceptor Transduction System. <i>Neurobiology of Learning and Memory</i> , 1995, 64, 49-57.	1.9	60
178	Synthesis and evaluation of tacrine-related compounds for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 1994, 29, 205-221.	5.5	28
179	Differential effects of physostigmine and 1,2,3,4-tetrahydro-9-aminoacridine on the $\beta$ -adrenoceptor transduction system. <i>European Journal of Pharmacology</i> , 1993, 245, 9-13.	2.6	4
180	Potentialiation of acute opioid-induced respiratory depression and reversal of tolerance by the calcium antagonist nimodipine in awake rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1993, 348, 633-637.	3.0	14

#	ARTICLE	IF	CITATIONS
181	The Ca <sup>2+</sup> channel agonist Bay K 8644 induces central respiratory depression in cats, an effect blocked by naloxone. <i>European Journal of Pharmacology</i> , 1993, 240, 155-161.	3.5	6
182	Post-train administration of 9-amino-1,2,3,4-tetrahydroacridine enhances passive avoidance retention and decreases $\hat{I}^2$ -adrenoceptor-linked cyclic AMP formation in middle-aged rats. <i>Brain Research</i> , 1992, 586, 117-120.	2.2	10
183	Acute effects of tetrahydroaminoacridine on $\hat{I}^2$ -adrenoceptor-linked cyclic AMP accumulation in brain of young and middle-aged rats. <i>Neuroscience Letters</i> , 1991, 132, 51-54.	2.1	5
184	Ca <sup>2+</sup> channel modulation by dihydropyridines modifies sufentanil-induced respiratory depression in cats. <i>European Journal of Pharmacology</i> , 1991, 198, 149-155.	3.5	13
185	Calcium channel modulation by dihydropyridines modifies sufentanil-induced antinociception in acute and tolerant conditions. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1990, 342, 559-65.	3.0	53
186	Respiratory actions induced by cholecystokinin at the brainstem level. <i>Peptides</i> , 1988, 9, 809-815.	2.4	13
187	Mechanism of the respiratory action of pentobarbital at the medullary and pontine levels. <i>European Journal of Pharmacology</i> , 1986, 125, 225-232.	3.5	7